Position in CGON
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$74,583,360
+$42,529,920 QoQ
Shares Held
1,102,000
+42.7% QoQ
Ownership
1.25%
of shares outstanding
% of Portfolio
3.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in CGON Over Time
Shares Held
Position Value (USD)
Derivatives in CGON
reported options exposure · as of Dec 31, 2025CallValue
$12,157,056
CallShares
292,800
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026EcoR1 Capital, LLC holds $2,284,236,973 across 26 Biotechnology names. CGON ranks #8 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ZYME |
Zymeworks Inc.
|
22,970,388 | $575,178,515 | |
| 2 | ANAB |
Anaptysbio, Inc
|
7,880,094 | $437,030,013 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
1,706,469 | $322,607,964 | |
| 4 | CNTA |
Centessa Pharmaceuticals plc
|
6,000,000 | $238,320,000 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
4,288,120 | $155,744,518 | |
| 6 | AKTS |
Aktis Oncology, Inc.
|
4,824,469 | $86,309,750 | |
| 7 | ORIC |
Oric Pharmaceuticals, Inc.
|
6,728,116 | $85,245,229 | |
| 8 | CGON |
CG Oncology, Inc.
This page
|
1,102,000 | $74,583,360 |
All Filings in CGON
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $74,583,360 | 1,102,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $32,053,440 | 772,000 | Shares | Sole | 2026-02-17 | |
| 2025-12-31 | $12,157,056 | 292,800 | Call | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||